Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531959 · ClinicalTrials.gov registry record · Phase 3
Midodrine for the Treatment of Refractory Hypotension
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
NCT01531959: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT01531959 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01531959, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
Study Summary
We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of stay without increasing MGH length of stay or putting the patient at risk of being readmitted to an ICU.
Interventions
- DRUG Placebo
- DRUG Midodrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2012-04 |
| Est. Completion | 2019-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531959
The ClinicalTrials.gov registry entry for NCT01531959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01531959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531959 about?
NCT01531959 is a clinical study titled "Midodrine for the Treatment of Refractory Hypotension". We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of stay without increasing MGH length of stay or putting the patient at risk of being readmitted to an ICU.
What is the current status of trial NCT01531959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2012-04. Estimated completion is 2019-06.
What interventions are being tested in trial NCT01531959?
The interventions under investigation include: Placebo (DRUG), Midodrine (DRUG).
Who is sponsoring clinical trial NCT01531959?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.